Magnetic Resonance Imaging in Acute Ischemic Stroke Treatment

Bum Joon Kim, Hyun Goo Kang, Hye-Jin Kim, Sung-Ho Ahn, Na Young Kim, Steven Warach, Dong-Wha Kang

Department of Neurology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea

Seton/University of Texas Southwestern Clinical Research Institute of Austin, TX, USA

Although intravenous administration of tissue plasminogen activator is the only proven treatment after acute ischemic stroke, there is always a concern of hemorrhagic risk after thrombolysis. Therefore, selection of patients with potential benefits in overcoming potential harms of thrombolysis is of great importance. Despite the practical issues in using magnetic resonance imaging (MRI) for acute stroke treatment, multimodal MRI can provide useful information for accurate diagnosis of stroke, evaluation of the risks and benefits of thrombolysis, and prediction of outcomes. For example, the high sensitivity and specificity of diffusion-weighted image (DWI) can help distinguish acute ischemic stroke from stroke-mimics. Additionally, the lesion mismatch between perfusion-weighted image (PWI) and DWI is thought to represent potential salvageable tissue by reperfusion therapy. However, the optimal threshold to discriminate between benign oligemic areas and the penumbra is still debatable. Signal changes of fluid-attenuated inversion recovery image within DWI lesions may be a surrogate marker for ischemic lesion age and might indicate risks of hemorrhage after thrombolysis. Clot sign on gradient echo image may reflect the nature of clot, and their location, length and morphology may provide predictive information on recanalization by reperfusion therapy. However, previous clinical trials which solely or mainly relied on perfusion-diffusion mismatch for patient selection, failed to show benefits of MRI-based thrombolysis. Therefore, understanding the clinical implication of various useful MRI findings and comprehensively incorporating those variables into therapeutic decision-making may be a more reasonable approach for expanding the indication of acute stroke thrombolysis.

Introduction

Ischemic stroke is one of the major causes of death and disability. For the last few decades, many efforts have been made to improve the outcome of acute ischemic stroke treatment. However, thrombolytic therapy is still the only proven treatment for patients following an acute ischemic stroke within 3 or 4.5 hours of symptom onset. Studies focusing on expansion of the therapeutic time window and indication for thrombolysis are ongoing, but the adverse effects stemming from reperfusion injury, including hemorrhagic transformation (HT) or massive edema are still a concern. Therefore, it is important to select appropriate patients based on an assessment of individual risks and benefits for thrombolysis.

Multimodal magnetic resonance imaging (MRI) is useful for diagnosing ischemic stroke and for determining treatment stra-
gies in the acute phase.\textsuperscript{45} In the acute stage, early diagnosis of ischemic stroke and its differentiation from stroke-mimics are important.\textsuperscript{6,7} Various imaging findings from MRI sequences help determine stroke mechanisms, which affect prognosis, and thereby play an important role in treatment decisions. Lesion mismatch profiles on MRI help us to assess potential risks and benefits of thrombolysis by providing information on salvageable tissue or ischemic lesion age.\textsuperscript{8-10}

Some of these parameters have been used in previous MRI-based thrombolysis trials, but the results were not satisfactory. While simply using a few parameters may be easily applicable, other valuable information for diagnosing stroke, determining the mechanism, and assessing the potential risks and benefits may be overlooked. Therefore, it is critical to understand the clinical implication of various imaging findings, and comprehensively consider them before deciding the treatment for acute stroke.

In this review, we discuss the clinical implication of various MRI findings, specifically focusing on 1) MRI for diagnosis of acute stroke and its mechanism, 2) MRI-based patient selection for reperfusion therapy, 3) MRI outcome measures, and 4) the practicality of using MRI for hyperacute stroke.

**Imaging for acute stroke diagnosis**

**Diagnosis of acute stroke**

Diagnosis of stroke largely depends on clinical presentation. Stroke-mimics account for 19%-30% of suspected stroke presentations, with diverse underlying etiology (Figure 1).\textsuperscript{11} Physicians need to consider a broad differential diagnosis when evaluating a patient presenting with a focal neurological deficit. With recent advances in MRI technology, ischemic lesions can be identified with high accuracy using diffusion-weighted image (DWI; 88%-100% sensitivity and 95%-100% specificity). The lesions appear as hyperintense areas on DWI and as correlative hypointense areas on apparent diffusion coefficient (ADC) maps, even within 3 minutes of stroke onset.\textsuperscript{12} Moreover, small cortical or subcortical lesions, especially in the posterior fossa or brain stem, are more easily detected by MRI than computed tomography (CT) at the acute stage. However, the small lesions located at the brain stem that present mild symptoms, especially ataxic hemiparesis or intranuclear ophthalmoplegia, could be invisible on initial DWI.\textsuperscript{13,14} In addition, other neurological diseases (i.e., Creutzfeldt-Jakob disease or progressive multifocal leukodystrophy) may also show high-intensity lesions on DWI, mimicking ischemic stroke.\textsuperscript{15,16} Therefore, considering clinical presentation as well as performing follow-up images may be beneficial for diagnosis.

**Assessing the mechanism of stroke**

Many studies have attempted to unravel stroke pathomechanism by ischemic lesion topography on DWI. It has been reported that multiple lesions in the unilateral anterior circulation or small, scattered lesions in one vascular territory are related to large artery atherosclerosis (Figure 2A, B).\textsuperscript{17} Perforating infarcts, in addition to pial or borderzone infarcts were distinctive pattern for intracranial atherosclerosis (Figure 2A).\textsuperscript{18,19} DWI also enables the detection of small lacunar infarcts that had previously been undetectable on CT. Fluid-attenuated inversion recovery (FLAIR) image demonstrate subacute or chronic ischemic lesions, which may help in classifying the subtype of index stroke.\textsuperscript{20} For example, recurrent deep perforating infarcts may develop in patients who have high burden of small vessel pathology.

Cardioembolism can be suspected when patients exhibit acute multiple territorial lesions\textsuperscript{3} or a single large cortical and subcortical lesion on DWI.\textsuperscript{21,22} Particularly, early spontaneous recanalization of initially occluded vessels or abrupt occlusion without other atherosclerotic diseases on magnetic resonance angiography (MRA) may suggest cardioembolic stroke (Figure 2C).\textsuperscript{23,24} Hypointense signals with blooming artifacts in the vascular cistern on gradient echo (GRE) image (susceptible vessel sign; SVS), which may reflect the presence of deoxygenated hemoglobin of red thrombi, are usually associated with cardioembolic stroke (Figure 2C).\textsuperscript{25} Patent foramen ovale, another source of cardioembolism, usually causes small cortical lesions in vertebral-basilar circulation, which may reflect high blood flow in the posterior circulation provoked by the Valsalva maneuver.\textsuperscript{26} Currently, aortic arch atherosclerosis is accepted as a possible embolic source in cryptogenic stroke, and the resulting ischemic lesion patterns and clinical outcomes differ from those of cardiogenic embolism. Moreover, aortic arch embolism has a higher propensity of causing left hemispheric stroke and multiple small infarcts (Figure 2D).\textsuperscript{27,28}
Early assessment of the etiology ischemic stroke in the acute stage using MRI is advantageous to guide specific diagnostic work-ups and proper strategy for hyperacute reperfusion therapy and secondary stroke prevention.

**Patient selection for acute stroke treatment**

**Evaluation of salvageable tissue**

**Concept of penumbra**

When the cerebral blood vessel is occluded, a complex series of pathophysiological events evolve in time and space. First, the core of the area rapidly develops an infarction (ischemic core). However, the surrounding part of the core still exhibits minimum blood flow supplied by collateral circulation, even when neuronal function has been suspended (ischemic penumbra). The neuronal function of some parts of the ischemic penumbra can recover when blood supply is restored, and goes through a dynamic change during the acute period of ischemic stroke.  

Perfusion-weighted image (PWI) can identify ischemic penumbral tissue, whereas DWI-depicted lesions represent the ischemic core. Therefore, areas with PWI-DWI mismatch (i.e., when the perfusion lesion is larger than the diffusion lesion) have been considered representative salvageable tissue that require active treatment (Figure 3A).

**PWI parameters**

PWI is a semi-quantitative method for evaluating brain perfusion - microcirculation in the capillary network. When a contrast agent is administered into a vein, it passes through cerebral vessels and alters the local magnetic field resulting in the rapid decrease of signal intensity in the surrounding brain tissue by the paramagnetic effect of the contrast. The variation of signal intensity is measured during 1 minute, serially with 1- to 2-second intervals by the echo-planar image technique. From this data, time-concentration curves can be obtained at the tissue level, voxel-by-voxel (Figure 3B). After deconvolution with arterial input functions, a deconvolved curve can be obtained (Figure 3C), and various perfusion parameters can be calculated. These parameters include cerebral blood flow (CBF), cerebral blood volume (CBV), mean transit time (MTT), time to peak (TTP), and Tmax (Figure 3D).

**CBF and CBV**

CBF is a parameter usually taken at the height of deconvolved curve (Figure 3C). It reflects the blood supply to the brain tissue in a given time and is most directly related to the viability of the infarcted tissue. CBF is determined by cerebral perfusion pressure, the dilation of blood vessels, and blood viscosity. An area with normal CBF and delayed MTT or TTP demonstrates an area with blood flow maintained by blood vessel dilation (increased CBV), but reaching the particular area late through collaterals. CBV is measured by the whole blood quantity within the target area (area under the deconvolved curve; Figure 3C). Areas of decreased CBV correlate well with the final size of a cerebral infarction. This is especially the case when the area of delayed MTT with decreased CBV represents the area of brain tissue not having sufficient collateral circulation; thus, these regions will eventually evolve into cerebral infarctions.

**MTT, TTP, and Tmax**

MTT is the average time required for blood flow to enter the artery and maintain the inside of the cerebral artery. MTT is calculated by CBV/CBF and is used to estimate vulnerable brain
tissue which may evolve from the infarction.\textsuperscript{36} MTT shows the widest range of perfusion deficits compared to other parameters, and is therefore likely to overestimate areas with risk. If an area with MTT delay shows increased CBV, that area may have received sufficient collateral circulation or may have been currently recanalized.\textsuperscript{33}

TTP describes the time it takes CBF to reach the highest value at the target tissue location (Figure 3B). TTP is an indirect measurement of brain perfusion; therefore, it provides minimum information. Since a delay in TTP can occur in a patient with chronic carotid artery stenosis without acute infarction (prolonged arrival time), TTP can also overestimate the hypoperfused area in an acute infarction.\textsuperscript{33}

Tmax is the time it takes for the tissue residue function to reach its maximum value. Tmax is a sensitive parameter reflecting changes of brain tissue into an infarction and changes in the perfusion state. Tmax has also been used as a predictor of tissue viability in many studies as a non-physiological parameter of the capability of brain tissue to survive. Since this parameter is not influenced by scan duration, Tmax has the merit that sufficient scanning for a long time is possible so that contrast agent can reach all parts.\textsuperscript{38} Thus, Tmax is the most widely accepted parameter to measure the penumbra.

\textit{PWI parameter thresholds in discriminating between penumbra and benign oligemic area}

Recent studies have focused on the threshold for distinguishing a true penumbra from a benign oligemia. Although time-based
perfusion variables are widely used methods assessing penumbra, there are still a lot of controversies on interpreting them.

Previously, many different thresholds for Tmax representing the true penumbra area have been suggested. For example, a Tmax > 6 seconds was defined as the penumbra in the Diffusion and Perfusion Imaging Evaluation for Understanding Stroke Evolution (DEFUSE) trial, whereas in the effects of alteplase beyond 3 hours after stroke in the Echoplanar Imaging Thrombolytic Evaluation (EPITHET) trial cohort, a Tmax of 4 to 6 seconds delay was used. Another study showed that a Tmax > 4 seconds delay provided the most accurate final infarct volume in patients within 3 to 6 hours after stroke onset. Compared with the penumbra measured from a positron emission tomography study, a Tmax ≥ 5.5 seconds delay matched most well. Recently, another study suggested that Tmax ≥ 10 seconds delay best predicts the final infarction.

Taken together, these studies indicate that there is no established criterion to discriminate between benign oligemic area and the penumbra. Although a number of studies have been conducted on Tmax threshold for that purpose, there are still a lot of controversies on the optimum criterion since the threshold value to determine the final infarction varies from study by study.

PWI-DWI mismatch in patient selection

Previously, PWI-DWI mismatch was used for patient selection in several clinical trials focusing on acute stroke treatment. In the DEFUSE study, patients with PWI-DWI mismatch in the 3 to 6 hours window demonstrated more favorable clinical response after reperfusion compared to patients without a PWI-DWI mismatch. However, this previous study had no placebo control group and it was not designed to demonstrate the efficacy of MRI-based intravenous thrombolysis. In the EPITHET study, infarct growth was compared between patients who received tissue plasminogen activator (tPA) and those who received a placebo. The primary outcome measure was the attenuation of infarct growth using a ratio of geometric means. However, their results failed to demonstrate beneficial outcomes of using PWI-DWI mismatch in thrombolysis. The Desmoteplase in Acute Ischemic Stroke (DIAS) clinical trial was a phase-II trial that employed a pre-randomization penumbral imaging screening as an indication for patient selection. Within 3-9 hours of symptom onset, patients with ischemic stroke and at least 20% PWI-DWI mismatch (as evaluated by visual inspection) were included in the trials. However, the results of the DIAS study have failed to prove the benefit of desmoteplase versus placebo in patients with MRI-identified penumbras.

The previous trials of imaging-based thrombolysis were solely or mostly based on PWI-DWI mismatch and failed to prove any advantages. These failures however, have reinforced the benefit of salvaging the penumbral tissue by thrombolysis, and the fact that HT risk should be considered when deciding to treat a patient via thrombolysis.

Hemorrhagic risk stratification after thrombolysis

Mechanisms and clinical implication

HT is a frequent, often asymptomatic event that occurs after acute ischemic stroke. It is thought to negatively influence the early clinical course and outcome of patients, particularly those receiving thrombolytic therapy. HT is presumed to occur in the infarcted brain area due to the extravasation of blood components. Disruption of the blood-brain barrier has been proposed to precede HT. In addition, the dose-dependent side effects of tPA treatment have been discussed as risk factors for HT. Early blood-brain barrier disruption is associated with HT even in patients who do not receive tPA treatment for stroke. This might be due to an increase in vascular permeability in ischemic tissue, resulting in a leakage from small vessels when exposed to restored blood flow.

Definition and classification of HT

In the European Cooperative Acute Stroke Study (ECASS) trials, the types of HT after acute ischemic stroke were classified into hemorrhagic infarctions (types 1 and 2) and parenchymal hemorrhages (types 1 and 2) on the basis of CT scan characteristics (Figure 4). In the NINDS tPA Stroke Trial, the definition of HT required blood to be detected by CT after treatment. Irrespective of other features, detection of any blood by CT in a patient with neurological deterioration qualified the patient for symptomatic HT. In the ECASS-II trial, investigators looked for an increase of more than 4 points on the National Institutes of Health Stroke Scale (NIHSS) score and detection of blood at any site by CT for this qualification. Finally, in ECASS-III, an increase of more than 4 points on the NIHSS score had to be “correlated” with blood detection by CT to suggest HT as the probable cause of neurological deterioration.

Factors associated with HT

Several factors are known to be associated with HT, and the combination of clinical and imaging data helps identify patients at high risk of symptomatic HT. Clinical factors such as a high initial NIHSS, delayed treatment time, and high blood pressure are well known to increase the incidence of HT and have been used as exclusion criteria for thrombolytic therapy. The imaging data indicative of a large infarct and early ischemic signs on CT are also widely used as exclusion criteria for thrombolytic therapy.
bolistic therapy. In fact, early ischemic changes were defined in the NINDS tPA trial as the presence of one or more of the following characteristics: 1) loss of grey-white matter distinction, 2) hypodensity (hypo-attenuation) of brain parenchyma, and 3) compression of CSF spaces. However, the sensitivity and reproducibility of early ischemic signs on brain CT is poor.

MRI predictors for HT

A low ADC value on baseline MRIs has been suggested as an independent predictor of HT after thrombolysis. Results of other studies have shown that large DWI lesion volume, or very low/absent apparent CBV or CBF can increase the risk of HT. Focal FLAIR hyperintensity within acute infarcts is also associated with an increased risk of symptomatic HT in several studies. The predictive value of silent microbleeds for HT after thrombolysis is unclear. Although their presence on GRE has been suggested to be predictive of increased HT risk after treatment with tPA, data from a large cohort study indicated that micro-hemorrhages were not an independent risk factor for early and symptomatic HT, irrespective of the number of microbleeds. In addition, a larger PWI lesion volume (a measure of ischemic duration) was associated with hemorrhagic infarction, but not with parenchymal hemorrhage.

Considering the pathomechanism of HT, radiological markers that directly indicate blood-brain barrier permeability could predict HT after acute ischemic stroke. In fact, it has been shown that contrast-enhancement can predict tPA-induced hemorrhages in rat models. These techniques have been assessed in humans, including delayed gadolinium enhancement of the CSF space (Figure 5A) or sulcal enlargement on FLAIR images, parenchymal enhancement on post-contrast T1-weighted images (Figure 5B), and permeability images derived from pretreatment perfusion MRIs.
Assessing the nature and burden of clots

Magnetic susceptibility artifacts distort ferromagnetic objects. Technically, shortening the echo-time, increasing the frequency matrix, and decreasing the slice thickness could reduce artifact size. On the other hand, magnetic susceptibility artifacts may also enhance the detection of red thrombi clots, which are ferromagnetic. As the composition, size, and site of clot occluding cerebral arteries are important factors for selecting the treatment strategy, GRE and SVS may be useful for treatment decisions. Initial, long-standing, platelet-rich, and well-organized white thrombi in the cerebral artery under high shear-stress are more resistant to thrombolytic therapy than fresh, fibrin-rich red thrombi formed under static conditions. Therefore, SVS is known as a marker with higher possibility of recanalization.69 Second, the location of a clot is also important. SVS of M1 is a strong predictor of recanalization failure after tPA.70 Therefore, intra-arterial thrombolysis may be more effective than tPA in certain cases. Third, the clot length is typically used to quantify the thrombotic burden.71 This is important since intra-venous tPA has nearly no potential to recanalize an MCA occlusion with a clot length exceeding 8 mm (Figure 6A).72 Finally, irregular and tortuous clot morphologies can decrease the technical
and clinical success of thrombectomies in M1 occlusions (Figure 6B). 73

MRI-based thrombolysis in unclear-onset patients

Physicians are frequently confronted with patients in whom the exact time of stroke symptom onset is not known, 74 and attempts have been made to use signal changes in FLAIR images as a kind of "tissue clock". 75 For example, it is known that signal intensity in FLAIR images proportionately increases with a rise in water content inside the infarcted tissue. The water content rises due to vasogenic edema as the blood-brain barrier is disrupted, and occurs within 1 to 4 hours of stroke onset. 76 Therefore, DWI-FLAIR mismatch (i.e., lesion visible on DWI but not on FLAIR) has been used as a surrogate marker for estimating the lesion age of unknown stroke onset, and can help determine the use of thrombolytic agent (Figure 7). 77,78 Patients with DWI-FLAIR mismatch are likely to be within the time window for thrombolysis, the specificity and predictive value of which have both been shown to be high (93% and 94%, respectively). 77 Finally, in the reperfusion therapy in unclear-onset stroke based on MRI evaluation (RESTORE), patients with unclear stroke onset, within 6 hours of symptom detection with PWI-DWI mismatch > 20% and negative or subtle FLAIR change, were treated with tPA or endovascular therapy, and MRI-based reperfusion therapy was found to be feasible and safe. 79

However, potential confounding factors that interfere with the diagnostic accuracy of DWI-FLAIR mismatch also exist. In addition to the time from symptom onset, younger age and large ischemic lesion volume have been reported to be associated with high FLAIR signal intensity. 7 As age and lesion size alter permeability in the blood-brain barrier, these biological variations may cause altered FLAIR signal intensity. 80 In addition, there is an issue stemming from the low inter-rater reliability of DWI-FLAIR mismatch. For example, in a previous study it was reported that the inter-rater reliability of FLAIR change was only moderate, based on visual rating. 7 In other studies, the mean signal intensity of a circular region-of-interest inside the infarcted tissue was quantitatively measured and used to overcome this issue, but even this approach failed to improve inter-rater reliability. 81 On the other hand, color-coding of FLAIR signal change has been reported to enhance visual distinguishability, and seems to be effective in decreasing the disagreement between raters. 82 Further results of the on-going trials may provide more knowledge on the risk and benefit of MRI-based thrombolysis in this particular group of patients. Table 1 introduces these major on-going clinical trials.

MRI-based thrombolysis in patients with minor stroke

One-third of acute ischemic strokes that have occurred within the therapeutic time window have been excluded because of mild or rapidly improving symptoms. 83 However, poor outcome in patients who did not receive tPA because of minor stroke symptoms has been reported with up to 30% of these patients at risk of death and dependence. 84 Moreover, a subgroup of patients with minor stroke and proximal vessel occlusion were found to be at higher risk of neurological deterioration. 84 Clinical criteria, such as NIHSS scores, are poorly predictive of proximal intracranial occlusion, and underestimate the risk of subsequent neurological deterioration. 85 Thus, off-label thrombolytic therapy was not associated with higher complication rates in cases of minor stroke. 86

MRI has been suggested as a tool to identify patients with minor stroke who may benefit from thrombolysis. In patients that have experienced a minor stroke, a significant mismatch can persist for days and their symptoms may aggravate without recanalization therapy. Recent studies have reported that treat-

Figure 7. DWI-FLAIR mismatch: positive (A) and negative (B).
At 90 days after stroke, MR mismatch score > 2
Infarct core < 70 mL

Primary endpoint
DWI-FLAIR mismatch (+)

Trial design
Place
Inclusion criteria

Table 1. On-going clinical trial to expand the time-window of intra-venous thrombolysis

| Trial name (identifier) | Trial design | Inclusion criteria | Sample size | MR-parameter for inclusion | Primary endpoint | Place |
|-------------------------|--------------|--------------------|-------------|---------------------------|-----------------|-------|
| WAKE-UP (NCT01525290)  | Multicenter  | Age: 18-80 Wake-up stroke or Unclear-onset stroke Patients within 4.5 hr of LNNT | 800 | DWI-FLAIR mismatch (+) | At 90 days after stroke, Favorable outcome: mRS (0-1) | Europe |
| EXTEND (NCT00897328)   | Multicenter  | Age: > 18 Wake-up stroke (< 9 hr from midpoint) or Patients within 3 or 4.5-9 hr of LNNT | 400 | Infarct core < 70 mL PWI-DWI lesion volume ratio > 1.2 PWI-DWI difference > 10 mL | At 90 days after stroke, Favorable outcome: mRS (0-1) | Australia, New Zealand |
| THAWS (NCT020202325)   | Multicenter  | Age: > 20 Wake up stroke (< 4.5 hr from FFAT) Unknown onset stroke 4.5-12 hr from LNNT NIHSS score: 5-25 | 300 | DWI-FLAIR mismatch (+) DWI ASPECT score > 5 | At 90 days after stroke, Favorable outcome: mRS (0-1) | Japan |
| MR WITNESS (NCT01282242) | Multicenter  | Age: 18-85 Wake up stroke and Unknown onset stroke (< 24 hr from LNNT and < 4.5 hr from FFAT) NIHSS score: < 26 | 80 | Brain MRI findings consistent with early stroke onset | No significant increase of symptomatic hemorrhage | United States |
| TAIS (NCT02101606)     | Single center | Age: > 18 Onset stroke < 24 hr from FFAT or LNNT NIHSS score: 4-18 | 20 | MR mismatch score > 2 | Symptomatic hemorrhagic trans-formation evident on MRI or CT on 24 h or day 5 | Canada |

LNNT, last known normal time; FFAT, first found abnormal time; DWI, diffusion-weighted image; FLAIR, fluid attenuated inversion recovery; PWI, perfusion-weighted image; MRI, magnetic resonance image; ASPECT, Alberta stroke program early CT; NIHSS, National Institutes of Health Stroke Scale.

ment with tPA based on PWI-DWI mismatch is safe and effective in patients with minor stroke. However, the lesion pattern, rather than the PWI-DWI mismatch, has been shown to be an important predictor of neurological decline in patients that have undergone a minor stroke. Still, no systematic data are available on the effect of IV-tPA in cases of minor stroke. Thus, only the inclusion of patients with minor stroke in future randomized controlled trials of intravenous thrombolysis will allow us to answer the question of whether thrombolysis is effective and safe in this group of patients.

MRI outcome measures

Clinical trials evaluating the success of thrombolysis have relied on various outcome parameters to measure how well an ischemic vascular bed responds to treatment. Usually, clinical parameters based on the severity of neurological deficits (NIHSS scores) or functional disability (modified Rankin Scale or Barthel Index) are used. However, as these clinical parameters are influenced by various confounders, including the lesion location or patient age, they do not directly demonstrate the treatment effect of salvaging the penumbral tissue. On the other hand, imaging parameters have an advantage in quantitatively measuring the effect of treatment by demonstrating the initial infarction core, penumbra, and the final infarction volume. The three main categories used in outcome measures by MRI are, 1) DWI lesion volume change, 2) PWI lesion volume change, and 3) recanalization of the occluded vessel on MRA.

Currently, there is no consensus on how to determine infarct growth. This measure has been based on the change in lesion volume between baseline and follow-up MRIs (DWI at 24 hours and FLAIR at 5 days). In the EPITHET study, various measures of infarction volume were suggested, such as geometric mean and the difference in cube-root volumes. However, measurement tools in the clinical setting should be easy to use, and PWI parameters used in the previous clinical trials differ from study to study. Thus, there are some difficulties in comparing the results of each study. For example, in the DEFUSE study, early reperfusion was defined as a more than 50% reduction in the volume of the PWI lesion (Tmax > 6 seconds). On the other hand, reperfusion in the EPITHET study was defined as > 90% reduction between baseline and day-3 PWI lesion volumes. This discrepancy is also seen in the DIAS study as the investigators defined reperfusion as ≥ 30% reduction of...
Basic principles

Absence of any antegrade flow beyond the target occlusion (no perfusion)
Antegrade flow beyond the target occlusion, without distal branch filling (penetration without perfusion)
Normal flow which fills all distal branches (complete perfusion)

Clinical implications

Gadolinium contrast injected and signal intensity drops as the contrast passes during fast scanning of T2*-weighted images
Pulse sequence, which inverses and recovers null fluids and represents the area with vasogenic edema
Basic sequence varied by adding de-phasing or re-phasing gradients to make flowing blood much brighter than stationary tissue
Gadolinium contrast injected and signal intensity drops as the contrast passes during fast scanning of T2*-weighted images
Time-of-flight MRA: uses a short echo time and flow compensation to make flowing blood much brighter than stationary tissue

Recanalization grading system

| Timi | Tici | AoL |
|------|------|-----|
| Poor revascularization | 0 | Absence of any antegrade flow beyond the target occlusion (no perfusion) | 0 | Complete occlusion of the primary occlusive lesion |
| Antegrade flow beyond the target occlusion, without distal branch filling (penetration without perfusion) | 1 | Antegrade perfusion beyond the occlusion, but limited distal branch filling with slow distal perfusion | 1 | Incomplete or partial recanalization of the primary occlusive lesion with no distal flow |
| Antegrade perfusion of less than half of the occluded artery ischemic territory | 2 | Antegrade perfusion of more than half of the occluded artery ischemic territory | 2 | Incomplete or partial recanalization of the occlusive lesion with any distal flow |
| Normal flow which fills all distal branches (complete perfusion) | 3 | Complete antegrade perfusion of the occluded target artery ischemic territory | 3 | Complete recanalization of the primary occlusive lesion with any distal flow |

TIMI, thrombolysis in myocardial infarction; TICI, thrombolysis in cerebral infarction; AOL, arterial occlusive lesion.

Table 3. Basic principles and clinical implications of multimodal MRI

| Sequence | Basic principles | Clinical implications |
|----------|-----------------|----------------------|
| DWI | Maps the diffusion process of water molecules and represents the area with cytotoxic edema | • Appears rapidly after ischemic insult as a high signal intensity lesion • High specificity and sensitivity of detecting ischemia • Lesion pattern differs according to stroke mechanism |
| FLAIR | Pulse sequence, which inverses and recovers null fluids and represents the area with vasogenic edema | • May reflect the time from stroke onset • Visible lesion increases the risk of hemorrhage after reperfusion therapy • Helps evaluate the burden of old white matter ischemic change |
| GRE | Basic sequence varied by adding de-phasing or re-phasing gradients at the end of the sequence, susceptibility artifact enhances the detection of ferromagnetic material | • Sensitive to detect hemorrhagic infarction or hemorrhagic transformation • Susceptible vessel sign is associated with red-blood cell rich clot |
| PWI | Gadolinium contrast injected and signal intensity drops as the contrast passes during fast scanning of T2*-weighted images | • Reveals the area of penumbral tissue • Represents the potential benefit of recanalization • Debates still exist in defining the threshold of the true penumbra |
| MRA | Time-of-flight MRA: uses a short echo time and flow compensation to make flowing blood much brighter than stationary tissue Contrast-enhanced MRA: uses contrast to obtain a high-resolution image of cerebral vessels | • Non-invasive technique to evaluate cerebral vessel stenosis or occlusion • No exposure to radiation or more nephrotoxic contrast agents compared to CT angiography |

MTT volume abnormality between baseline and follow-up images.^{42}

Two distinct measures for assessing recanalization have been used to evaluate the effectiveness of thrombolytic therapy. First, recanalization of the primary arterial occlusive lesion has been evaluated using the Arterial Occlusive Lesion (AOL) grading system. Second, reperfusion of the distal vascular bed has been evaluated using the Thrombolysis in Myocardial Infarction (TIMI) and the Thrombolysis in Cerebral Infarction (TICI) grading system (Table 2). However, the use of multiple scales has resulted in some confusion and limits the comparison among studies.

In the Intervventional Management of Stroke (IMS)-1 trial,^{92} the AOL grading system was used. However, recanalization of the primary arterial occlusive lesion does not guarantee complete reperfusion of the downstream arterioles. The TIMI definition, which has been used to describe flow in the coronary arteries, was adapted to evaluate the degree of reperfusion.^{93,94} Therefore, in order to emphasize the use of a standard grading system specific to intracranial circulation, a TICI grading system has been suggested.^{95} Recently, the TICI grading system is regarded as the most reliable parameter for recanalization. While there are some limitations of angiography based scales, combining the scales with MR perfusion may be a good parameter for treatment outcome.

Correlation of MRI parameters and clinical outcome

It is important to ask whether MRI parameters are correlated with clinical outcomes. In fact, it has been shown that early infarct growth within the first week can predict long-term clinical outcome after thrombolysis.^{96} Specifically, when recanalization scores were dichotomized into poor (AOL 0-2, TIMI 0-1, and
TICI 0-2a) versus good revascularization (AOL 3, TIMI 2-3, TICI 2b-3), investigators found a significant difference between the two groups (Table 2). Moreover, it was revealed that patients with good clinical outcomes (modified Rankin scale 0-2) had smaller infarct growth, smaller perfusion growth, and good revascularization.97

**Practicality of MRI for use in hyperacute stroke**

Multimodal MRI reveals various useful parameters for deciding treatment routes of acute stroke (Table 3). This technology is especially useful when stroke diagnosis is uncertain (stroke-mimics), stroke onset is unclear (wake-up or unwitnessed daytime strokes), or clinic-imaging mismatches exist. However, in spite of the potential benefits of MRI, practical issues exist limiting the use of MRI in the acute stage of ischemic stroke.98 One of the major issues is the long scan time when compared to CT. In general, although MRI-based decisions of thrombolysis have prolonged the door-to-needle time, the clinical outcome has been more favorable.99,100 Therefore, the use of MRI in acute stroke treatment is clinically practical and feasible.101,102 On the other hand, considering that “time is brain” in the hyperacute stage of ischemic stroke, minimizing the evaluation time taken for the decision of treatment may expand the benefit of thrombolysis. Interestingly, a recent study revealed a feasible diagnostic quality of 6-minute multimodal MRI using echo-planar FLAIR and GRE in patients with acute ischemic stroke, and this may enhance the usage of MRI in acute stroke treatment.103 The effect and usefulness of this paradigm in acute stroke treatment should be verified by future trials. In addition, various new MRI advancements are actively under research, such as arterial spin labeling, techniques to measure collateral flows, computational flow dynamics, and high-resolution vessel-wall MRI. These novel imaging biomarkers may be helpful in determining the treatment strategy for acute ischemic stroke.

**Conclusion**

Multimodal imaging provides information that is useful for diagnosing ischemic stroke, selecting appropriate patients for thrombolytic therapy, and predicting the prognosis of ischemic stroke. Only depending on a single or a few parameters may not be sufficient, instead comprehensively combining the information from each MRI sequence (i.e., DWI, FLAIR, GRE, and PWI) and using various mismatch parameters (DWI-FLAIR mismatch and/or PWI-DWI mismatch) may be more helpful in establishing an indication of MRI-based thrombolysis.

**References**

1. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. *N Engl J Med* 1995;333:1581-1587.
2. Hacke W, Kaste M, Bluhmki E, Brozman M, Davalos A, Guidetti D, et al. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. *N Engl J Med* 2008;359:1317-1329.
3. Khatri R, McKinney AM, Swenson B, Janardhan V. Blood-brain barrier, reperfusion injury, and hemorrhagic transformation in acute ischemic stroke. *Neurology* 2012;79:552-557.
4. Baird AE, Warach S. Magnetic resonance imaging of acute stroke. *J Cereb Blood Flow Metab* 1998;18:583-609.
5. Campbell BC, Tu HT, Christensen S, Desmond PM, Levi CR, Bladin CF, et al. Assessing response to stroke thrombolysis: validation of 24-hour multimodal magnetic resonance imaging. *Arch Neurol* 2012;69:46-50.
6. Lovblad KO, Laubach HJ, Baird AE, Curtin F, Schlaug G, Edelman RR, et al. Clinical experience with diffusion-weighted MR in patients with acute stroke. *Am J Neuroradiol* 1998;19:1061-1066.
7. Chalela JA, Kang DW, Luby M, Ezzeddine M, Latour LL, Todd JW, et al. Early magnetic resonance imaging findings in patients receiving tissue plasminogen activator predict outcome: Insights into the pathophysiology of acute stroke in the thrombolysis era. *Ann Neurol* 2004;55:105-112.
8. Schlaug G, Benfield A, Baird AE, Siewert B, Lovblad KO, Parker RA, et al. The ischemic penumbra: operationally defined by diffusion and perfusion MRI. *Neurology* 1999;53:1528-1537.
9. Thomalla G, Cheng B, Ebinger M, Hao Q, Toudias T, Wu O, et al. DWI-FLAIR mismatch for the identification of patients with acute ischaemic stroke within 4.5 h of symptom onset (PRE-FLAIR): a multicentre observational study. *Lancet Neurol* 2011;10:978-986.
10. Neumann-Haefelin T, Wittsack HJ, Wenserski F, Siebler M, Seitz RJ, Modder U, et al. Diffusion- and perfusion-weighted MRI. The DWI/PWI mismatch region in acute stroke. *Stroke* 1999;30:1591-1597.
11. Gibson LM, Whiteley W. The differential diagnosis of suspected stroke: a systematic review. *J R Coll Physicians Edinb* 2013;43:114-118.
12. Warach S, Gaa J, Siewert B, Wielopolski P, Edelman RR. Acute human stroke studied by whole brain echo planar diffusion-weighted magnetic resonance imaging. *Ann Neurol* 1995;37:231-241.
13. Sylaja PN, Coutts SB, Krol A, Hill MD, Demchuk AM; VISION Study Group. When to expect negative diffusion-weight-
ed images in stroke and transient ischemic attack. Stroke 2008; 39:1898-1900.
14. Balami JS, Chen RL, Buchan AM. Stroke syndromes and clinical management. QJM 2013;106:607-615.
15. Kallenberg K, Schulz-Schaeffer WJ, Jastrow U, Poser S, Meissner B, Tschampa HJ, et al. Creutzfeldt-Jakob disease: comparative analysis of MR imaging sequences. Am J Neuroradiol 2006; 27:1459-1462.
16. Bergui M, Bradac GB, Oguz KK, Boghi A, Geda C, Gatti G, et al. Progressive multifocal leukoencephalopathy: diffusion-weighted imaging and pathological correlations. Neuroradiology 2004;46:22-25.
17. Kang DW, Chalela JA, Ezzeddine MA, Warach S. Association of ischemic lesion patterns on early diffusion-weighted imaging with TOAST stroke subtypes. Arch Neurol 2003;60:1730-1734.
18. Lee DK, Kim JS, Kwon SU, Yoo SH, Kang DW. Lesion patterns and stroke mechanism in atherosclerotic middle cerebral artery disease: early diffusion-weighted imaging study. Stroke 2005;36:2583-2588.
19. Bang OY. Intracranial atherosclerosis: current understanding and perspectives. J Stroke 2014;16:27-35.
20. Nah HW, Kang DW, Kwon SU, Kim JS. Diversity of single small subcortical infarctions according to infarct location and parent artery disease: analysis of indicators for small vessel disease and atherosclerosis. Stroke 2010;41:2822-2827.
21. Cho AH, Kim JS, Jeon SB, Kwon SU, Lee DH, Kang DW. Mechanism of multiple infarcts in multiple cerebral circulations on diffusion-weighted imaging. J Neurol 2007;254:924-930.
22. Jung JM, Kwon SU, Lee JH, Kang DW. Difference in infarct volume and patterns between cardioembolism and internal carotid artery disease: focus on the degree of cardioembolic risk and carotid stenosis. Cerebrovasc Dis 2010;29:490-496.
23. Cho KH, Lee DH, Kwon SU, Choi CG, Kim SJ, Suh DC, et al. Factors and outcomes associated with recanalization timing after thrombolysis. Cerebrovasc Dis 2012;33:255-261.
24. Cho AH, Kwon SU, Kim JS, Kang DW. Evaluation of early dynamic changes of intracranial arterial occlusion is useful for stroke etiology diagnosis. J Neurol Sci 2012;312:127-130.
25. Cho KH, Kim JS, Kwon SU, Cho AH, Kang DW. Significance of susceptibility vessel sign on T2*-weighted gradient echo imaging for identification of stroke subtypes. Stroke 2005;36:2379-2383.
26. Kim BJ, Sohn H, Sun BJ, Song JK, Kang DW, Kim JS, et al. Imaging characteristics of ischemic strokes related to patent foramen ovale. Stroke 2013;44:3350-3356.
27. Jung JM, Kwon JY, Kim HJ, Kwon SU, Song JK, Kim JS, et al. Ischemic lesion burden and characteristics of aortic atheroma. J Stroke Cerebrovasc Dis 2014;23:278-282.
28. Kim YS, Park SS, Bae HJ, Heo JH, Kwon SU, Lee BC, et al. Public awareness of stroke in Korea: a population-based national survey. Stroke 2012;43:1146-1149.
29. Dirdagl U, Iadecola C, Moskowitz MA. Pathobiology of ischemic stroke: an integrated view. Trends Neurosci 1999;22:391-397.
30. Banerjee RK, Back LH, Back MR, Cho YI. Physiological flow analysis in significant human coronary artery stenoses. Biomech 2003;40:451-476.
31. Tatlisumak T, Strbian D, Abo Ramadan U, Li F. The role of diffusion- and perfusion-weighted magnetic resonance imaging in drug development for ischemic stroke: from laboratory to clinics. Curr Vasc Pharmacol 2004;2:343-355.
32. Jahng GH, Kim HS, Kim SM, Ryu CW. Principles and technical aspects of perfusion magnetic resonance imaging. J Korean Soc Magn Reson Med 2011;15:91-101.
33. Heo SH, Seo JJ, Yim NY, Jeong GW, Yoon W, Kim YH. Acute cerebral infarction in a rabbit model: perfusion and diffusion MR imaging. J Korean Soc Magn Reson Med 2003;7:116-123.
34. Jeon HW, Kang JH, Lee SY, Lee YS, Kang MJ, Cha JK. Can diffusion-perfusion mismatch on brain MRI in acute ischemic stroke patients predict clinical outcome? Preliminary Study Focused on rCBV. J Korean Neurol Assoc 2008;26:295-300.
35. Copen WA, Schaefer PW, Wu O. MR perfusion imaging in acute ischemic stroke. Neuroimaging Clin N Am 2011;21:259-283.
36. Albers GW, Thijs VN, Wechsler L, Kemp S, Schlaug G, Ska-labrin E, et al. Magnetic resonance imaging profiles predict clinical response to early reperfusion: the diffusion and perfusion imaging evaluation for understanding stroke evolution (DEFUSE) study. Ann Neurol 2006;60:508-517.
37. Donnan GA, Baron JC, Ma H, Davis SM. Penumbral selection of patients for trials of acute stroke therapy. Lancet Neurol 2009;8:261-269.
38. Olivot JM, Mlynash M, Thijs VN, Kemp S, Lansberg MG, Wechsler L, et al. Optimal Tmax threshold for predicting penumbral tissue in acute stroke. Stroke 2009;40:469-475.
39. Nagakane Y, Christensen S, Ogata T, Churilov L, Ma H, Parsons MW, et al. Moving beyond a single perfusion threshold to define penumbra: a novel probabilistic mismatch definition. Stroke 2012;43:1548-1555.
40. Albers GW, Thijs VN, Wechsler L, Kemp S, Schlaug G, Ska-labrin E, et al. Magnetic resonance imaging profiles predict clinical response to early reperfusion: the diffusion and perfusion imaging evaluation for understanding stroke evolution (DEFUSE) study. Ann Neurol 2006;60:508-517.
41. Davis SM, Donnan GA, Parsons MW, Levi C, Butcher KS,
Peeters A, et al. Effects of alteplase beyond 3 h after stroke in the Echoplanar Imaging Thrombolytic Evaluation Trial (EPI-THET): a placebo-controlled randomised trial. Lancet Neurol 2008;7:299-309.

42. Hacke W, Albers G, Al-Rawi Y, Bogousslavsky J, Davalos A, Eliasziw M, et al. The Desmoteplase in Acute Ischemic Stroke Trial (DIAS): a phase II MRI-based 9-hour window acute stroke thrombolysis trial with intravenous desmoteplase. Stroke 2005; 36:66-73.

43. Kimura K, Iuchi Y, Shibazaki K, Kobayashi K, Uemura J, Aoki J, et al. Recanalization between 1 and 24 hours after t-PA therapy is a strong predictor of cerebral hemorrhage in acute ischemic stroke patients. J Neurol Sci 2008;270:48-52.

44. Fisher M, Adams RD. Observations on brain embolism with special reference to the mechanism of hemorrhagic infarction. J Neuropathol Exp Neurol 1951;10:92-94.

45. Ogata J, Yutani C, Imakita M, Ishibashi-Ueda H, Saku Y, Mine-matsu K, et al. Hemorrhagic infarct of the brain without a reopening of the occluded arteries in cardioembolic stroke. Stroke 1989;20:876-883.

46. Simard JM, Kent TA, Chen M, Tarasov KV, Gerzanich V. Brain oedema in focal ischaemia: molecular pathophysiology and theoretical implications. Lancet Neurol 2007;6:258-268.

47. Burggraf D, Martens HK, Jager G, Hamann GF. Recombinant human tissue plasminogen activator protects the basal lamina in experimental focal cerebral ischemia. Thromb Haemost 2003; 89:1072-1080.

48. Warach S, Latour LL. Evidence of reperfusion injury, exacerbated by thrombolytic therapy, in human focal brain ischemia using a novel imaging marker of early blood-brain barrier disruption. Stroke 2004;35:2659-2661.

49. Hacke W, Kaste M, Fieschi C, von Kummer R, Davalos A, Albers G, et al. Predictors of hemorrhagic transformation after intravenous recombinant tissue plasminogen activator: prognostic value of the initial apparent diffusion coefficient and diffusion-weighted lesion volume. Stroke 2002;33:2047-2052.

50. Butcher K, Christensen S, Parsons M, De Silva DA, Ebinger M, Levi C, et al. Postthrombolysis blood pressure elevation is associated with hemorrhagic transformation. Stroke 2010;41: 72-77.

51. Selim M, Fink JN, Kumar S, Caplan LR, Horkan C, Chen Y, et al. Predictors of hemorrhagic transformation after intravenous recombinant tissue plasminogen activator: prognostic value of the initial apparent diffusion coefficient and diffusion-weighted lesion volume. Stroke 2002;33:2047-2052.

52. Adams HP Jr, del Zoppo G, Alberts MJ, Bhatt DL, Brass L, Furlan A, et al. Guidelines for the early management of adults with ischemic stroke: a guideline from the American Heart Association/American Stroke Association Stroke Council, Clinical Cardiology Council, Cardiovascular Radiology and Intervention Council, and the Atherosclerotic Peripheral Vascular Disease and Quality of Care Outcomes in Research Interdisciplinary Working Groups: the American Academy of Neurology affirms the value of this guideline as an educational tool for neurologists. Stroke 2007;38:1655-1711.

53. Grotta JC, Chiu D, Lu M, Patel S, Levine SR, Tilley BC, et al. Agreement and variability in the interpretation of early CT changes in stroke patients qualifying for intravenous rtPA therapy. Stroke 1999;30:1528-1533.

54. Alsop DC, Makovetskaya E, Kumar S, Selim M, Schlaug G. Markedly reduced apparent blood volume on bolus contrast magnetic resonance imaging as a predictor of hemorrhage after thrombolytic therapy for acute ischemic stroke. Stroke 2005; 36:746-750.

55. Cho AH, Kim JS, Kim SJ, Yun SC, Choi CG, Kim HR, et al. Focal fluid-attenuated inversion recovery hyperintensity within acute diffusion-weighted imaging lesions is associated with symptomatic intracerebral hemorrhage after thrombolysis. Stroke 2008;39:3424-3426.

56. Kidwell CS, Saver JL, Villablanca JP, Duckwiler G, Fredieu A, Gough K, et al. Magnetic resonance imaging detection of microbleeds before thrombolysis: an emerging application. Stroke 2002;33:95-98.

57. Koennecke HC. Cerebral microbleeds on MRI: prevalence, associations, and potential clinical implications. Neurology 2006; 66:165-171.

58. Thomalla G, Sobesky J, Kohrmann M, Fiebach JB, Fiehler J, Zaro Weber O, et al. Two tales: hemorrhagic transformation but not parenchymal hemorrhage after thrombolysis is related to severity and duration of ischemia: MRI study of acute stroke patients treated with intravenous tissue plasminogen activator within 6 hours. Stroke 2007;38:313-318.

59. Neumann-Haefelin C, Brinker G, Uhlenkuken U, Pillekamp F, Hossmann KA, Hoehn M. Prediction of hemorrhagic transformation after thrombolytic therapy of clot embolism: an MRI
investigation in rat brain. Stroke 2002;33:1392-1398.
63. Cho AH, Cho YP, Lee DH, Kwon TW, Kwon SU, Suh DC, et al. Reperfusion injury on magnetic resonance imaging after carotid revascularization. Stroke 2014;45:602-604.
64. Cho AH, Suh DC, Kim GE, Kim JS, Lee DH, Kwon SU, et al. MRI evidence of reperfusion injury associated with neurologic deficits after carotid revascularization procedures. Eur J Neurol 2009;16:1066-1069.
65. Latour LL, Kang DW, Ezzeddine MA, Chalela JA, Warach S. Early blood-brain barrier disruption in human focal brain ischemia. Ann Neurol 2004;56:468-477.
66. Kim EY, Kim SS, Na DG, Roh HG, Ryoo JW, Kim HK. Sulcal hyperintensity on fluid-attenuated inversion recovery imaging in acute ischemic stroke patients treated with intra-arterial thrombolysis: iodinated contrast media as its possible cause and the association with hemorrhagic transformation. J Comput Assist Tomogr 2005;29:264-269.
67. Hjort N, Wu O, Ashkanian M, Solling C, Mouridsen K, Christensen S, et al. MRI detection of early blood-brain barrier disruption: parenchymal enhancement predicts focal hemorrhagic transformation after thrombolysis. Stroke 2008;39:1025-1028.
68. Bang OY, Buck BH, Saver JL, Alger JR, Yoon SR, Starkman S, et al. Prediction of hemorrhagic transformation after recanalization therapy using T2*-permeability magnetic resonance imaging. Ann Neurol 2007;62:170-176.
69. Molina CA, Montaner J, Arenillas JF, Ribo M, Rubiera M, Alvarez-Sabin J. Differential pattern of tissue plasminogen activator-induced proximal middle cerebral artery recanalization among stroke subtypes. Stroke 2004;35:486-490.
70. Kimura K, Ichigi Y, Shibazaki K, Watanabe M, Iwanaga T, Aoki J. M1 susceptibility vessel sign on T2* as a strong predictor for no early recanalization after IV-t-PA in acute ischemic stroke. Stroke 2009;40:3130-3132.
71. Riedel CH, Jensen U, Rohr A, Tietke M, Allke K, Ulmer S, et al. Assessment of thrombus in acute middle cerebral artery occlusion using thin-slice nonenhanced Computed Tomography reconstructions. Stroke 2010;41:1659-1664.
72. Riedel CH, Zimmermann P, Jensen-Kondering U, Stingele R, Deuschl G, Jansen O. The importance of size: successful recanalization by intravenous thrombolysis in acute anterior stroke depends on thrombus length. Stroke 2011;42:1775-1777.
73. Zhu L, Liebeskind DS, Jahan R, Starkman S, Salamon N, Duckwiler G, et al. Thrombus branching and vessel curvature are important determinants of middle cerebral artery trunk recanalization with Merci thrombectomy devices. Stroke 2012;43:787-792.
74. Kang DW, Kwon JY, Kwon SU, Kim JS. Wake-up or unclear-onset strokes: are they waking up to the world of thrombolysis therapy? Int J Stroke 2012;7:311-320.
75. Thomalla G, Gerloff C. We are on the clock: MRI as a surrogate marker of lesion age in acute ischemic stroke. Stroke 2010;41:197-198.
76. Burdette JH, Ricci PE, Petitti N, Elster AD. Cerebral infarction: time course of signal intensity changes on diffusion-weighted MR images. Am J Roentgenol 1998;171:791-795.
77. Thomalla G, Rossbach P, Rosenkranz M, Siemonsen S, Krtzelmann A, Fiehler J, et al. Negative fluid-attenuated inversion recovery imaging identifies acute ischemic stroke at 3 hours or less. Ann Neurol 2009;65:724-732.
78. Kim BJ, Kim HJ, Lee DH, Kwon SU, Kim SJ, Kim JS, et al. Diffusion-weighted image and fluid-attenuated inversion recovery image mismatch: unclear-onset versus clear-onset stroke. Stroke 2014;45:450-455.
79. Kang DW, Sohn SI, Hong KS, Yu KH, Hwang YH, Han MK, et al. Reperfusion therapy in unclear-onset stroke based on MRI evaluation (RESTORE): a prospective multicenter study. Stroke 2012;43:3278-3283.
80. Dankbaar JW, Hom J, Schneider T, Cheng SC, Lau BC, van der Schaaf I, et al. Age- and anatomy-related values of blood-brain barrier permeability measured by perfusion-CT in non-stroke patients. J Neuroradiol 2009;36:219-227.
81. Galinovic I, Puig J, Neeb L, Guibemard N, Kemmling A, Siemonsen S, et al. Visual and region of interest-based inter-rater agreement in the assessment of the diffusion-weighted imaging-fluid-attenuated inversion recovery mismatch. Stroke 2014;45:1170-1172.
82. Kim BJ, Kim YH, Kim YJ, Ahn SH, Lee DH, Kwon SU, et al. Color-coded FLAIR images improve inter-rater reliability of FLAIR signal changes within acute DWI lesions. Stroke 2014;45:2801-2804.
83. Barber PA, Zhang J, Demchuk AM, Hill MD, Buchan AM. Why are stroke patients excluded from TPA therapy? An analysis of patient eligibility. Neurology 2001;56:1015-1020.
84. Nedeltchev K, Schwegler B, Haefeli T, Brekenfeld C, Gralla J, Fischer U, et al. Outcome of stroke with mild or rapidly improving symptoms. Stroke 2007;38:2531-2535.
85. Kim JT, Park MS, Kim MK, Cho KH. Minor stroke with total mismatch after acute MCA occlusion. J Neuroimaging 2011;21:399-402.
86. Breuer L, Blinzer C, Huttner HB, Kiphuth IC, Schwab S, Kohrmann M. Off-label thrombolysis for acute ischemic stroke: rate, clinical outcome and safety are influenced by the definition of ‘minor stroke’. Cerebrovasc Dis 2011;32:177-185.
87. Kohrmann M, Nowe T, Huttner HB, Engelhorn T, Struffert
145

T, Kollmar R, et al. Safety and outcome after thrombolysis in stroke patients with mild symptoms. *Cerebrovasc Dis* 2009; 27:160-166.

88. Kim JT, Yoon GJ, Nam TS, Choi SM, Lee SH, Park MS, et al. Internal border zone lesions as a predictor of early neurological deterioration in minor stroke patients with severe arterial steno-occlusion. *J Neuroimaging* 2011;21:173-176.

89. Johnston KC, Wagner DP, Wang XQ, Newman GC, Thijss V, Sen S, et al. Validation of an acute ischemic stroke model: does diffusion-weighted imaging lesion volume offer a clinically significant improvement in prediction of outcome? *Stroke* 2007; 38:1820-1825.

90. Parsons MW, Barber PA, Chalk J, Darby DG, Rose S, Desmond PM, et al. Diffusion- and perfusion-weighted MRI response to thrombolysis in stroke. *Ann Neurol* 2002;51:28-37.

91. Lansberg MG, Straka M, Kemp S, Mlynash M, Wechsler LR, Jovin TG, et al. MRI profile and response to endovascular reperfusion after stroke (DEFUSE 2): a prospective cohort study. *Lancet Neurol* 2012;11:860-867.

92. Khatri P, Neff J, Broderick JP, Khoury JC, Carrozella J, Tomsick T. Revascularization end points in stroke interventional trials: recanalization versus reperfusion in IMS-I. *Stroke* 2005; 36:2400-2403.

93. TIMI Study Group. The Thrombolysis in Myocardial Infarction (TIMI) trial. Phase I findings. *N Engl J Med* 1985;312:932-936.

94. Furlan A, Higashida R, Wechsler L, Gent M, Rowley H, Kase C, et al. Intra-arterial prourokinase for acute ischemic stroke. The PROACT II study: a randomized controlled trial. Prolyse in Acute Cerebral Thromboembolism. *JAMA* 1999;282:2003-2011.

95. Marks MP, Lansberg MG, Mlynash M, Olivit JM, Straka M, Kemp S, et al. Effect of collateral blood flow on patients undergoing endovascular therapy for acute ischemic stroke. *Stroke* 2014;45:1035-1039.

96. Cho KH, Kwon SU, Lee DH, Shim W, Choi C, Kim SJ, et al. Early infarct growth predicts long-term clinical outcome after thrombolysis. *J Neurol Sci* 2012;316:99-103.

97. Marks MP, Lansberg MG, Mlynash M, Kemp S, McTaggart R, Zaharchuk G, et al. Correlation of AOL recanalization, TIMI reperfusion and TICI reperfusion with infarct growth and clinical outcome. *J Neurointerv Surg* 2013.

98. Singer OC, Sitzer M, du Mesnil de Rochemont R, Neumann-Haefelin T. Practical limitations of acute stroke MRI due to patient-related problems. *Neurology* 2004;62:1848-1849.

99. Yoo SH, Kwon SU, Lee DH, Kim SJ, Kim JS, Kang DW. Comparison between MRI screening and CT-plus-MRI screening for thrombolysis within 3 h of ischemic stroke. *J Neurol Sci* 2010; 294:119-123.

100. Chalela JA, Kidwell CS, Nentwich LM, Laby M, Butman JA, Demchuk AM, et al. Magnetic resonance imaging and computed tomography in emergency assessment of patients with suspected acute stroke: a prospective comparison. *Lancet* 2007; 369:293-298.

101. Merino JG, Warach S. Imaging of acute stroke. *Nat Rev Neurol* 2010;6:560-571.

102. Kang DW, Chalela JA, Dunn W, Warach S; NIH-Suburban Stroke Center Investigators. MRI screening before standard tissue plasminogen activator therapy is feasible and safe. *Stroke* 2005;36:1939-1943.

103. Nael K, Khan R, Choudhary G, Meshka S, Villablanc P, Tay J, et al. Six-minute magnetic resonance imaging protocol for evaluation of acute ischemic stroke: pushing the boundaries. *Stroke* 2014;45:1985-1991.